Compare Bristol-Myers Squibb Co (BMY) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs General Dynamics Corporation — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while General Dynamics Corporation trades at $370.25 (market cap $99.92B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | GD | |
|---|---|---|
Market Cap | $116.30B | $99.92B |
Sector | Health | Industrials |
52-Week High | $62.37 | $376.88 |
52-Week Low | $42.60 | $297.05 |
Enterprise Value | $152.24B | $106.10B |
Dividend Yield | 4.42% | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
General Dynamics (GD) trades at $372.78, down 0.61% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.10 versus $3.67 expected, and maintains solid fundamentals including 8.07% net income margin and 17.97% ROE. Revenue growth continues, reaching $52.55 billion in 2025, with a robust backlog of $130.8 billion highlighting strong demand in naval and defense sectors.
Outlook remains positive driven by defense spending tailwinds and submarine contract momentum, though valuation multiples like P/E of 23.46 suggest limited upside near-term. Risks include execution on large contracts and geopolitical volatility. Analyst consensus is bullish with a $395.83 price target, indicating ~6% potential appreciation from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
